Get the Stockscreener App
22.84
3.91%
0.86
After Hours:
22.84
Uniqure N V stock is traded at $22.84, with a volume of 1.56M.
It is up +3.91% in the last 24 hours and up +4.34% over the past month.
uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
See More
Previous Close:
$21.98
Open:
$21.98
24h Volume:
1.56M
Relative Volume:
0.51
Market Cap:
$1.42B
Revenue:
$14.34M
Net Income/Loss:
$-199.00M
P/E Ratio:
-5.8265
EPS:
-3.92
Net Cash Flow:
$-183.51M
1W Performance:
-9.79%
1M Performance:
+4.34%
6M Performance:
+58.39%
1Y Performance:
+60.73%
1-Day Range:
$21.70
$23.34
1-Week Range:
$21.15
$25.11
52-Week Range:
$7.76
$71.50
Uniqure N V Stock (QURE) Company Profile
Name
Uniqure N V
Sector
Industry
Phone
1-339-970-7000
Address
PAASHEUVELWEG 25A, AMSTERDAM
Compare QURE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
22.84 | 1.37B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-04-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-14-25 | Upgrade | Mizuho | Neutral → Outperform |
| Apr-01-25 | Resumed | Chardan Capital Markets | Buy |
| Dec-10-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Feb-29-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-19-23 | Downgrade | Mizuho | Buy → Neutral |
| Mar-17-22 | Upgrade | UBS | Neutral → Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-21-21 | Initiated | UBS | Neutral |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-01-21 | Upgrade | Mizuho | Neutral → Buy |
| Jan-07-21 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-24-20 | Initiated | H.C. Wainwright | Buy |
| Nov-11-20 | Initiated | Berenberg | Buy |
| Nov-09-20 | Initiated | Jefferies | Buy |
| Nov-04-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
| Aug-25-20 | Initiated | Raymond James | Strong Buy |
| Jul-31-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jun-25-20 | Downgrade | Mizuho | Buy → Neutral |
| Jun-25-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jun-25-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-03-19 | Initiated | Cowen | Outperform |
| Dec-03-19 | Initiated | Goldman | Buy |
| Nov-05-19 | Initiated | Credit Suisse | Outperform |
| Oct-11-19 | Initiated | Stifel | Buy |
| Sep-25-19 | Initiated | Bernstein | Outperform |
| Sep-12-19 | Initiated | Mizuho | Buy |
| Jul-30-19 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-08-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Mar-29-19 | Initiated | Robert W. Baird | Outperform |
View All
Uniqure N V Stock (QURE) Latest News
QURE Investigation Reminder: Kessler Topaz Meltzer & - GlobeNewswire
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - GlobeNewswire Inc.
uniQure (QURE) Surges 17.9% Ahead of 2 Health Conferences - MSN
Setup Watch: Is AMPGW subject to activist investor interestEarnings Risk Report & Growth Focused Stock Pick Reports - baoquankhu1.vn
Downgrade Watch: Will uniQure NV stock benefit from M ALong Setup & Daily Market Momentum Tracking - baoquankhu1.vn
Robert Gut Sells 25,613 Shares of uniQure (NASDAQ:QURE) Stock - MarketBeat
RSI Check: Can uniQure NV continue delivering strong returnsJuly 2025 Snapshot & AI Powered Market Entry Ideas - baoquankhu1.vn
Health Check: How Prudently Does UniQure (NASDAQ:QURE) Use Debt? - 富途牛牛
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com Nigeria
uniQure stock rating reiterated at Overweight by Cantor Fitzgerald By Investing.com - Investing.com Australia
uniQure stock falls after FDA feedback on gene therapy application - MSN
Ideas Watch: Does uniQure NV stock trade at a discount to peersJuly 2025 Outlook & Daily Chart Pattern Signal Reports - moha.gov.vn
How Investors Are Reacting To uniQure (QURE) After Its Pivotal FDA Type A Meeting On AMT-130 - Yahoo Finance
Assessing uniQure (QURE) Valuation After Recent Volatility And Gene Therapy Progress - Yahoo Finance
uniQure updates gene therapy pipeline and regulatory outlook - TipRanks
uniQure N.V. Updates on Gene Therapy Developments - TradingView — Track All Markets
uniQure (NASDAQ:QURE) Director Sells $174,319.20 in Stock - MarketBeat
uniQure (NASDAQ:QURE) Shares Down 9.2%Should You Sell? - MarketBeat
QURE Investigation Reminder: Kessler Topaz Meltzer & Check, - GlobeNewswire
Is UniQure (QURE) One of the Promising Stocks to Buy Under $50? - Insider Monkey
uniQure Shares Skyrocket After Positive Huntington’s Disease Gene Therapy Data - MSN
uniQure (NASDAQ:QURE) Rating Lowered to Sell at Wall Street Zen - MarketBeat
uniQure N.V. Investigation Notice: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure N.V. Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - NewMediaWire
uniQure (NASDAQ:QURE) Shares Gap UpHere's What Happened - MarketBeat
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy - Investing.com Nigeria
uniQure (QURE) Surges on FDA Meeting for Gene Therapy Approval - GuruFocus
UniQure Announces FDA Type A Meeting To Discuss BLA Data For Huntington's Gene Therapy - Nasdaq
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy - Investing.com
US-listed shares of uniQure rise 13% premarket as FDA review talks revive hopes for Huntington's therapy - marketscreener.com
uniQure's (QURE) Gene Therapy for Huntington's Disease Advances with FDA Meeting - GuruFocus
uniQure gains as FDA sets up meeting on gene therapy (QURE:NASDAQ) - Seeking Alpha
uniQure stock soars after FDA meeting scheduled on Huntington’s therapy By Investing.com - Investing.com South Africa
uniQure prepares for FDA Type A meeting on AMT-130 - TipRanks
uniQure schedules FDA meeting to discuss accelerated approval for HD therapy By Investing.com - Investing.com South Africa
uniQure Announces Type A Meeting Scheduled with FDA - The Manila Times
uniQure N.V. Schedules FDA Meeting for AMT-130 Approval - TradingView — Track All Markets
FDA to review data on experimental Huntington's gene therapy at uniQure - Stock Titan
UniQure N.V. (QURE) Stock Analysis: A Biotech Powerhouse With 137% Potential Upside - DirectorsTalk Interviews
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourage - GuruFocus
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors with Significant Losses to Contact the Firm - Prime Publishers, Inc.
Is uniQure N.V. stock supported by strong fundamentals2025 Risk Factors & Verified Momentum Stock Alerts - ulpravda.ru
uniQure: Now What? (NASDAQ:QURE) - Seeking Alpha
How sustainable is uniQure N.V. stock dividend payout2025 Growth vs Value & Weekly Market Pulse Alerts - ulpravda.ru
Pullback Watch: Is uniQure N.V. stock attractive for long term wealth building2025 Market Outlook & Weekly Hot Stock Watchlists - ulpravda.ru
QURE Investigation: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
How (QURE) Movements Inform Risk Allocation Models - Stock Traders Daily
QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP - Business Wire
Wells Fargo Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $60 - 富途牛牛
QURE Investigation: Kessler Topaz Meltzer & Check, LLP Encourages uniQure N.V. (NASDAQ: QURE) Investors With Significant Losses to Contact the Firm - FinancialContent
uniQure (NASDAQ:QURE) Upgraded at Wall Street Zen - MarketBeat
Uniqure N V Stock (QURE) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):